Novartis Q1 Profit Tumbles 18% on Generic Competition, Manufacturing Problems (NVS)

By
A A A
Share |

Drug maker Novartis AG ( NVS ) on Tuesday said its first quarter earnings fell 18% from last year, hurt by competition from new generic drugs as well as production problems in the U.S.

The Swiss company reported first quarter net income of $2.33 billion, down from $2.82 billion in the year-ago period. Net sales fell 2% from last year to $13.74 billion.

Those results were largely in-line with what analysts had predicted.

On a sour note, Novartis said it expects full-year 2012 earnings to come in below 2011 levels.

Novartis shares fell 85 cents, or -1.5%, in morning trading Tuesday.

The Bottom Line
We recently began recommending shares of Novartis ( NVS ) since Mar.21, when the stock price was at $55.46. The company has a 4.42% dividend yield, based on last night's closing stock price of $55.62.

Novartis AG ( NVS ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: NVS

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

100%

Most Active by Volume

37,162,377
  • $16.9671 ▼ 0.49%
32,803,164
  • $13.45 ▼ 5.21%
28,081,226
  • $14.595 ▼ 1.32%
27,478,828
  • $76.65 ▼ 3.02%
26,535,502
  • $97.6301 ▼ 1.17%
22,674,496
  • $25.1348 ▼ 0.14%
21,192,433
  • $3.46 ▼ 0.86%
21,181,109
  • $99.68 ▼ 1.06%
As of 10/1/2014, 12:07 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com